BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.

AI/ML

Biotechnology

Pharmaceutical

Therapeutics

BigHat Bio

Mark DePristo

Randy Schreckhise

Vi Vu

Abiy Seifu

John Corbin

Mitchell Stieg

Leslie Grab

Danielle Landrein

Timothy Park

Charbel Eid

Eddie Abrams

Liz Schwarzbach

Peyton Greenside

The Research Team at BigHat Bio is dedicated to advancing antibody therapeutics through innovative experimental approaches and cutting-edge machine learning technologies. This multidisciplinary team conducts high-speed characterization and protein purification to accelerate antibody engineering, driving the development of safer and more effective treatments for challenging diseases. Through seamless integration of experimental and computational expertise, the team plays a pivotal role in BigHat Bio’s mission to improve human health.

Research Team

Software Development Team

Advisory Team

Research Team

About

Team members

Other teams at BigHat Bio

Software Development Team

Advisory Team